Project Kent

    Submission Date: 24/04/18
    Completion Date: 08/03/18
    Target: Xstrahl Group
    Acquirer: Risk Capital Partners
    Deal Value: undisclosed
    Deal Description: Charles Russell Speechlys advised on the sale of Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology, to Risk Capital Partners as part of a management buyout. The firm acted for Martin Robinson, the majority shareholder and previous CEO, from whom the business was acquired.
    Funding: Private Equity
    Corporate Finance Advisers: Lock Dutton Corporate Finance
    Legal Advisers: Charles Russell Speechlys
    Financial Due Diligence: RSM
    Commercial Due Diligence: Mansfield